A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency
Latest Information Update: 17 Aug 2022
At a glance
- Drugs Somatrogon (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors OPKO Health; PROLOR Biotech
- 14 Nov 2020 This trial is Completed in Netherland (Global End Date: 20 Aug 2018), according to European Clinical Trials Database record.
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database
- 10 May 2019 This trial has been completed in Austria according to European Clinical Trials Database